key: cord-1025565-bf6vjbu0
authors: Moreira-Soto, Andres; Arguedas, Mauricio; Brenes, Hebleen; Buján, Willem; Corrales-Aguilar, Eugenia; Díaz, Cecilia; Echeverri, Ann; Flores-Díaz, Marietta; Gómez, Aarón; Hernández, Andrés; Herrera, María; León, Guillermo; Macaya, Román; Kühne, Arne; Molina-Mora, José Arturo; Mora, Javier; Sanabria, Alfredo; Sánchez, Andrés; Sánchez, Laura; Segura, Álvaro; Segura, Eduardo; Solano, Daniela; Soto, Claudio; Stynoski, Jennifer L.; Vargas, Mariángela; Villalta, Mauren; Reusken, Chantal B E M; Drosten, Christian; Gutiérrez, José María; Alape-Girón, Alberto; Drexler, Jan Felix
title: High efficacy of therapeutic equine hyperimmune antibodies against SARS-CoV-2 variants of concern
date: 2021-06-14
journal: bioRxiv
DOI: 10.1101/2021.06.12.448080
sha: 4e66a854316c851949e9f196639577341699b24e
doc_id: 1025565
cord_uid: bf6vjbu0

SARS-CoV-2 variants of concern (VoC) show reduced neutralization by vaccine-induced and therapeutic monoclonal antibodies. We tested therapeutic equine polyclonal antibodies (pAbs) against four VoC (alpha, beta, epsilon and gamma). We show that equine pAbs efficiently neutralize VoC, suggesting they are an effective, broad coverage, low-cost and a scalable COVID-19 treatment.

Abstract 39 SARS-CoV-2 variants of concern (VoC) show reduced neutralization by vaccine-induced and 40

therapeutic monoclonal antibodies. We tested therapeutic equine polyclonal antibodies 41 (pAbs) against four VoC (alpha, beta, epsilon and gamma). We show that equine pAbs 42 efficiently neutralize VoC, suggesting they are an effective, broad coverage, low-cost and a 43 scalable COVID-19 treatment. 44 45 To the editor: SARS-CoV-2 causes coronavirus infectious disease 19 (COVID-19), which 46 leads to either critical illness or death in 5% of patients (1). COVID-19 prevention and 47 treatment options include vaccines, antivirals, and antibody formulations. A wide array of 48 vaccine platforms have shown efficacy in preventing severe disease, but universal access is 49 limited and many resource-limited settings largely lack sufficient vaccine coverage (2). Even 50 though there are more than 300 therapeutic drugs in clinical trials, few have proven 51 advantageous, such as dexamethasone (1, 3). Direct-acting antivirals like Remdesivir are 52 most effective if given very early, require supplementary oxygen therapy and are very costly 53 at 2,000-3,000 USD per treatment, limiting universal access (4). Convalescent plasma or 54 hyperimmune globulins, which can be prepared from the pooling of many donors, have been 55 used for decades to treat diseases such as ebola and influenza and could be a more affordable 56 at 350-1,000 USD per treatment. However, their preparation is donor-dependent, requires 57 strict donor rigorous testing for both blood-borne pathogens and high levels of neutralizing 58 anti-SARS-CoV-2 antibodies, not readily available on blood bank systems in many 59 developing countries (5). The use of monoclonal antibodies (mAbs) are safe alternatives 60 shown to enhance viral clearance, but their large scale production is challenging and costly, at 61 around 1,500-6,500 USD per treatment (6). A low-cost alternative to mAbs are formulations 62 of intact or fragmented equine polyclonal antibodies (pAbs), widely used for decades as 63 therapies against viral infections or as antivenoms. 64

We and others have previously shown that horses can be efficiently immunized with different 65 SARS-CoV-2 antigens to yield high quantities of purified polyclonal antibodies (pAbs) that 66 are 50-80 times more potent than convalescent plasma (7, 8). A formulation of equine 67 polyclonal F(ab') 2 fragments against the receptor binding domain (RBD) of SARS-CoV-2 68 was tested in a multi-center, double-blind, placebo-controlled phase II/III clinical trial 69

showing that it is well tolerated and leads to clinical improvement of hospitalized patients 70 with moderate to severe COVID-19 (9). Additionally, there is an ongoing randomized, multi-71 center, double-blind, placebo-controlled, dose-finding, phase IIb/III clinical trial 72 (NCT04838821) at hospitals of the Costa Rican Social Security Fund testing equine pAbs 73 formulations to treat moderate and severe COVID-19 cases. 74

However, pre-clinical data of equine hyperimmune pAbs are only available for early SARS-75

CoV-2 isolates, such data are lacking for recent and globally circulating variants, considered 76 of concern (VoC) due to their increased transmissibility. Voc alpha, beta, epsilon and gamma 77 both equine pAbs formulations the differences between potencies against tested VoC and 97 early SARS-CoV-2 isolates were not statistically significant (sum-of-squares F test of Anti-98 S1; p=0.9, Anti-Mix, p=0.8). 99

Our data suggest high potential of equine pAbs for treatment of COVID-19. By shifting 100 antivenom platforms to produce equine pAbs, laboratories in both developed and developing 101 countries that have been manufacturing and distributing safe and standardized antivenoms for 102 decades could rapidly fill the gaps in global demand for therapies that are both effective 103 against VoC and affordable to low-and middle-income countries. 104

We declare no competing interests. 106

This work was supported by the "Global Centres for Health and Pandemic Prevention" from 108 the German academic exchange services (DAAD). 109 110 8

The serum-virus solution was incubated at 37°C for 1 h and added to the cells. After 1 h at 160 37°C, supernatants were discarded, and cells were supplemented with 1.2% Avicel solution 161 in DMEM. After 3 d at 37°C, supernatants were removed, and the 24-well plates were fixed 162 and inactivated using a 6% formaldehyde/PBS solution and stained with crystal violet, and 163 plaques were counted. 164 165 166 167

Annex figure. IC50 dose-response curves to SARS-CoV-2 early isolates and variants of 168 concern named using WHO and Pango/Nextrain designations. The Y axis denotes the mean 169 plaque forming units (PFU) per milliliter in triplicate. The X axis denotes the Log10 170 concentration of the Anti-S1 and the Anti-Mix (combination of S1, N and SEM mosaic 171 protein of Wuhan-Hu-1, Accession N YP_009724390.1) formulations. 

Characteristics of SARS-CoV-2 and COVID-19

The Equitable Distribution of COVID-19 115 Therapeutics and Vaccines

Dexamethasone in Hospitalized Patients with Covid-19

Remdesivir for the Treatment of Covid-19 -Final Report

The Lancet H. The resurgence of convalescent plasma therapy

COV2, a Neutralizing Antibody Cocktail

Development of a hyperimmune equine serum therapy for COVID-19 in Argentina

Development and characterization of two equine formulations towards SARS-CoV-2 proteins 131 for the potential treatment of COVID-19

133 RBD-specific polyclonal F(ab´)(2) fragments of equine antibodies in patients with moderate 134 to severe COVID-19 disease: A randomized, multicenter, double-blind, placebo-controlled, 135 adaptive phase 2/3 clinical trial

Resistance of 137 SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal